Spark Therapeutics Announces Participation and Attendance for Conferences in June
- Presenting at the
Goldman Sachs37th Annual Global Healthcare Conference on Tuesday June 7, 2016, at 4:00 pm (PT), at the Terranea Resort, Rancho Palos Verdes, CA.
- Presenting at the 2016
BIO International Convention, at the Moscone Center, San Francisco, CA.
Daniel Takefman, head of regulatory affairs; Genetic Medicines Come of Age: The Challenges and Opportunities; Tuesday June 7, 2016, at 2:15 pm (PT) Jeffrey D. Marrazzo, chief executive officer; Curative Therapies: Aligning Policy with Science to Ensure Patient Access; Wednesday June 8, 2016, at 10:45 am (PT)
Katherine High, president and chief scientific officer; Gene Therapy or CRISPR: Which One Will Change the Future of Medical Care?; Thursday June 9, 2016, at 9:00 am (PT)
- Presenting at the
Jefferies2016 Healthcare Conference on Friday June 10, 2016, at 2:00 pm (ET), at the Grand Hyattin New York City, New York.
Katherine Highwill present at the European Hematology Associationpress briefing on Saturday June 11, 2016, at 8:30 amCentral European Time (CET), and Dr. Spencer Sullivan, clinical investigator on the trial, will present the abstract data on June 11at 5:30 pm (CET), in Copenhagen, Denmark.
- Attending the
Roth Capital Partners3rd Annual ROTH Healthcare Day on Wednesday June 22, 2016in London.
- Attending the J.P. Morgan 4th Annual
European Healthcare Conferenceon Thursday June 23, 2016in London.
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. To learn more, please visit www.sparktx.com.
Spark Therapeutics, Inc. Stephen W. WebsterChief Financial Officer (888) 772-7560 Media Ten Bridge Communications Dan Quinn(781) 475-7974 email@example.com